Biologic drug survival in Israeli psoriasis patients - 18/04/17
, Arnon D. Cohen, MD, MPH, PhD c, d, Michael Ziv, MD e, Cohen Barak Eran, MD e, Ilan Feldhamer, MsC f, Tamar Freud, MHA, PhD d, Eitan Berman, MD a, Shirley Oren, MD g, Emmilia Hodak, MD h, i, Lev Pavlovsky, MD, PhD h, ⁎ Abstract |
Background |
Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional systemic treatments in biologic survival is still unknown.
Objective |
To investigate the drug survival rates of biologic treatments in patients with psoriasis and to identify predictor factors.
Methods |
Survival analysis was performed on patients with severe psoriasis who received adalimumab, infliximab, etanercept, and ustekinumab for treatment of psoriasis, drawn from the Clalit Health Services database. Multivariate analysis was performed adjusting for demographic variables; metabolic syndrome and its components; psoriatic arthritis; biologic naivety; coadministration of methotrexate, acitretin, or cyclosporine; and previous standard systemic treatment exposure.
Results |
Among 907 patients treated with 1575 biologic treatments, ustekinumab had a significantly higher survival rate than tumor necrosis factor inhibitors. Biologic naivety and concomitant methotrexate intake were positive predictors for drug survival, whereas the female sex and the duration of previous systemic treatments were negative predictors.
Limitations |
Data regarding disease severity or duration could not be drawn from the Clalit Health Services database.
Conclusion |
Ustekinumab had better retention rates in comparison with other investigated biologics in patients with severe psoriasis, most of whom used it as a third line therapy.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, biologic medications, drug survival, etanercept, infliximab, psoriasis, ustekinumab
Abbreviations used : ADA, ANOVA, BADBIR, BMI, CHS, ETN, HMO, IFX, TNFI, UST
Plan
| Drs Shalom, Cohen, Hodak, and Pavlovsky contributed equally. |
|
| Funding source: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 76 - N° 4
P. 662 - avril 2017 Retour au numéro
Article précédent
- Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
- Bruce Strober, Alice B. Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G. Lebwohl
- Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
- ?ukasz Matusiak, Justyna Szcz?ch, Andrzej Bieniek, Danuta Nowicka-Suszko, Jacek C. Szepietowski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?